Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial

Table 4 Baseline and 24 months laboratory tests for renal function and lipids

Patients	baseline creatinine	24 month creatinine	baseline proteinuria¹	24 month proteinuria¹	baseline cholesterol/	24 month cholesterol/	baseline triglycerides	24 month triglycerides
	(mg/dL)/MDRD (ml/min/1.73m2)	(mg/dL)/ MDRD (ml/min/1.73m2)	(mg/mmol)	(mg/mmol)	HDL/LDL	HDL/LDL	(mmol/L)	(mmol/L)
					(mmol/L)	(mmol/L)
1	0.84 /76	0.78/81	6.1	12.1	159/89/90	184/74/101	45	52
2	0.93/>90	0.95/>90	22.4	40.0 ⁵	118/46/72	167/54/100	43	63
3	1.22/74		22.5	²	205/74/131		86
4	0.96/71		10.3	³	176/83/94	³	144	³
5	0.99/87	0.97/88	9.1	8.2	202/63/139	181/44/125 ⁴	116	64
6	0.67/>90	0.58/>90	5.0	9.6	240/86/156	152/63/89 ⁴	198	116
7	1.15/50 ⁰	0.98/60	9.4	28.6 ⁵	192/78/114	188/77/102	47	47
8	1.07/83	1.09/80	5.6	4.0	154/56/98	202/66/120	62	77
9	0.77/>90	0.86/>90	13.2	47.0 ⁵	125/36/90	226/52/136 ⁴	102	186
10	0.85/78	0.77/87	5.0	4.3	212/55/157	167/75/82 ⁴	48	51
11	0.71/>90 ⁰	0.86/78	7.7	9.4	94/40/54	118/41/64	76	62
12	0.42/> 90	0.48/>90	13.3	11.1	142/38/104	193/42/127	117	120
13	0.62/>90	0.61/>90	6.6	9.8	183/96/87	163/84/90	53	41
14	0.83/>90	1.01/>90	6.4	8.9	203/83/120	176/39/104 ⁴	175	163
15	0.68/>90	0.69/>90	9.0	18.2	200/78/122	170/75/80	66	73
16	0.62/>90	0.54/>90	12.9	11.9	156/51/105	120/49/50 ⁴	145	104
17	1.30/42 ⁰	1.24/44	22.4	32.3 ⁵	292/106/189	216/69/147 ⁴	243	117

0-Patients 7, 11, 17 had undergone a nephrectomy at least one year before the start of the trial.
1-Expressed as a protein-to-creatinine ratio.
2-Patient 3 was withdrawn at 12 months of treatment due to nephrotic-range proteinuria that reverted after discontinuation of treatment.
3-Patient 4 was excluded at 10 months due to acute pyelonephritis and did not want to be rechallenged.
4-Statins were prescribed in patients 5, 6, 9, 10, 14, 16, 17.
5- ACEI were prescribed for microalbuminuria in patients 2, 7, 9, 17.

ISSN: 1750-1172